行情

TTNP

TTNP

Titan制药
NASDAQ

实时行情|Nasdaq Last Sale

0.2188
-0.0042
-1.88%
盘后: 0.2194 +0.0006 +0.27% 19:50 04/03 EDT
开盘
0.2300
昨收
0.2230
最高
0.2310
最低
0.2120
成交量
253.74万
成交额
--
52周最高
2.180
52周最低
0.1420
市值
2,045.06万
市盈率(TTM)
-0.2222
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测TTNP价格均价为8.50,最高价位16.00,最低价为1.000。

EPS

TTNP 新闻

更多
  • Edited Transcript of TTNP earnings conference call or presentation 30-Mar-20 8:30pm GMT
  • Thomson Reuters StreetEvents · 4天前
  • Penny Stocks to Buy Using Technical Analysis for April 2020
  • Investopedia · 5天前
  • The Daily Biotech Pulse: Amarin Faces Legal Setback, Milestone Payment Kicks In For CytomX, Savara, Reata Disclose COVID-19 Disruptions
  • Benzinga · 5天前
  • Titan Pharmaceuticals, Inc. (TTNP) CEO Sunil Bhonsle on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 6天前

所属板块

制药
-0.14%
制药与医学研究
-0.22%

热门股票

代码
价格
涨跌幅

TTNP 简况

Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company's segment is engaged in the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery platform, ProNeura. The Company's drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan's ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson's disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism.
展开

微牛提供Titan Pharmaceuticals, Inc.(NASDAQ-TTNP)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的TTNP股票新闻,以帮助您做出投资决策。